Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

Table 5 Follow-up

In case of progressive disease after study treatment only:
• Survival, disease status, protracted toxicity, further treatment
In any other case additionally:
• Disease assessment, physical examination including weight, ECOG-performance status
• Blood draw for translational research at progression

ISSN: 1471-2407